<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Edgewise Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/edgewise-therapeutics-inc</link>
<description>Latest news and press releases for Edgewise Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 10 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/edgewise-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835657d78dffbe2df0f019d.webp</url>
<title>Edgewise Therapeutics Inc</title>
<link>https://6ix.com/company/edgewise-therapeutics-inc</link>
</image>
<item>
<title>Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up</title>
<link>https://6ix.com/company/edgewise-therapeutics-inc/news/edgewise-announces-positive-long-term-sevasemten-data-demonstrating-sustained-functional-stabilization-in-becker-muscular-dystrophy-through-35-years-of-follow-up</link>
<guid isPermaLink="true">https://6ix.com/company/edgewise-therapeutics-inc/news/edgewise-announces-positive-long-term-sevasemten-data-demonstrating-sustained-functional-stabilization-in-becker-muscular-dystrophy-through-35-years-of-follow-up</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>–The MESA data show stabilization of function in participants on sevasemten versus the predicted functional decline observed in Becker natural history studies</description>
</item>
<item>
<title>Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026</title>
<link>https://6ix.com/company/edgewise-therapeutics-inc/news/edgewise-therapeutics-to-present-at-the-leerink-global-healthcare-conference-on-march-11-2026-17</link>
<guid isPermaLink="true">https://6ix.com/company/edgewise-therapeutics-inc/news/edgewise-therapeutics-to-present-at-the-leerink-global-healthcare-conference-on-march-11-2026-17</guid>
<pubDate>Wed, 04 Mar 2026 05:00:00 GMT</pubDate>
<description>BOULDER, Colo., March 4, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced</description>
</item>
<item>
<title>Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference</title>
<link>https://6ix.com/company/edgewise-therapeutics-inc/news/edgewise-therapeutics-to-present-on-sevasemten-for-the-treatment-of-becker-muscular-dystrophy-at-the-2026-mda-clinical-and-scientific-conference</link>
<guid isPermaLink="true">https://6ix.com/company/edgewise-therapeutics-inc/news/edgewise-therapeutics-to-present-on-sevasemten-for-the-treatment-of-becker-muscular-dystrophy-at-the-2026-mda-clinical-and-scientific-conference</guid>
<pubDate>Tue, 03 Mar 2026 05:00:00 GMT</pubDate>
<description>BOULDER, Colo., March 3, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced</description>
</item>
<item>
<title>Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs</title>
<link>https://6ix.com/company/edgewise-therapeutics-inc/news/edgewise-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-with-strong-progress-across-muscular-dystrophy-and-cardiovascular-programs</link>
<guid isPermaLink="true">https://6ix.com/company/edgewise-therapeutics-inc/news/edgewise-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-with-strong-progress-across-muscular-dystrophy-and-cardiovascular-programs</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>– CIRRUS-HCM 12-week data of EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) expected in H1 2026 –– Phase 1 healthy adult trial</description>
</item>
<item>
<title>Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026</title>
<link>https://6ix.com/company/edgewise-therapeutics-inc/news/edgewise-therapeutics-present-guggenheim-emerging-outlook-biotech-summit-2026</link>
<guid isPermaLink="true">https://6ix.com/company/edgewise-therapeutics-inc/news/edgewise-therapeutics-present-guggenheim-emerging-outlook-biotech-summit-2026</guid>
<pubDate>Thu, 05 Feb 2026 05:00:00 GMT</pubDate>
<description>BOULDER, Colo., Feb. 5, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced</description>
</item>
<item>
<title>Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules</title>
<link>https://6ix.com/company/edgewise-therapeutics-inc/news/edgewise-therapeutics-reports-inducement-grants-permitted-nasdaq-listing-rules-2026-0</link>
<guid isPermaLink="true">https://6ix.com/company/edgewise-therapeutics-inc/news/edgewise-therapeutics-reports-inducement-grants-permitted-nasdaq-listing-rules-2026-0</guid>
<pubDate>Mon, 02 Feb 2026 05:00:00 GMT</pubDate>
<description>BOULDER, Colo., Feb. 2, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease</description>
</item>
<item>
<title>Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026</title>
<link>https://6ix.com/company/edgewise-therapeutics-inc/news/edgewise-therapeutics-provides-corporate-updates-and-highlights-priorities-2026-2026</link>
<guid isPermaLink="true">https://6ix.com/company/edgewise-therapeutics-inc/news/edgewise-therapeutics-provides-corporate-updates-and-highlights-priorities-2026-2026</guid>
<pubDate>Tue, 13 Jan 2026 05:00:00 GMT</pubDate>
<description>- Advancing robust clinical pipeline of novel therapeutics for muscular dystrophies and serious cardiac conditions -- Presenting at the 44th Annual J.P.</description>
</item>
<item>
<title>Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026</title>
<link>https://6ix.com/company/edgewise-therapeutics-inc/news/edgewise-therapeutics-present-44th-annual-jp-morgan-healthcare-conference-january-13</link>
<guid isPermaLink="true">https://6ix.com/company/edgewise-therapeutics-inc/news/edgewise-therapeutics-present-44th-annual-jp-morgan-healthcare-conference-january-13</guid>
<pubDate>Tue, 06 Jan 2026 05:00:00 GMT</pubDate>
<description>BOULDER, Colo., Jan. 6, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced</description>
</item>
<item>
<title>Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy</title>
<link>https://6ix.com/company/edgewise-therapeutics-inc/news/edgewise-therapeutics-announces-completion-edg-7500-cirrus-hcm-phase-2-parts-b-and-c</link>
<guid isPermaLink="true">https://6ix.com/company/edgewise-therapeutics-inc/news/edgewise-therapeutics-announces-completion-edg-7500-cirrus-hcm-phase-2-parts-b-and-c</guid>
<pubDate>Wed, 24 Dec 2025 05:00:00 GMT</pubDate>
<description>– In the CIRRUS-HCM trial, including interim safety results from Part D, EDG-7500 was generally well tolerated; no clinically meaningful reductions in LVEF or</description>
</item>
<item>
<title>Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors</title>
<link>https://6ix.com/company/edgewise-therapeutics-inc/news/edgewise-therapeutics-appoints-commercial-biotech-executive-christopher-martin-its</link>
<guid isPermaLink="true">https://6ix.com/company/edgewise-therapeutics-inc/news/edgewise-therapeutics-appoints-commercial-biotech-executive-christopher-martin-its</guid>
<pubDate>Thu, 20 Nov 2025 05:00:00 GMT</pubDate>
<description>BOULDER, Colo., Nov. 20, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today</description>
</item>
<item>
<title>Edgewise Therapeutics Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers</title>
<link>https://6ix.com/company/edgewise-therapeutics-inc/news/edgewise-therapeutics-announces-appointment-michael-nofi-chief-financial-officer-and</link>
<guid isPermaLink="true">https://6ix.com/company/edgewise-therapeutics-inc/news/edgewise-therapeutics-announces-appointment-michael-nofi-chief-financial-officer-and</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>BOULDER, Colo., Nov. 10, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing</description>
</item>
<item>
<title>Edgewise Therapeutics to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/edgewise-therapeutics-inc/news/edgewise-therapeutics-participate-upcoming-investor-conferences-2025-11-07</link>
<guid isPermaLink="true">https://6ix.com/company/edgewise-therapeutics-inc/news/edgewise-therapeutics-participate-upcoming-investor-conferences-2025-11-07</guid>
<pubDate>Fri, 07 Nov 2025 05:00:00 GMT</pubDate>
<description>BOULDER, Colo., Nov. 7, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced</description>
</item>
<item>
<title>Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/edgewise-therapeutics-inc/news/edgewise-therapeutics-reports-third-quarter-2025-financial-results-and-recent</link>
<guid isPermaLink="true">https://6ix.com/company/edgewise-therapeutics-inc/news/edgewise-therapeutics-reports-third-quarter-2025-financial-results-and-recent</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>– Pivotal GRAND CANYON cohort of sevasemten in Becker expected to read out in Q4 2026; building infrastructure to support potential commercial launch – –</description>
</item>
<item>
<title>Edgewise Therapeutics to Present on Sevasemten for Becker and Duchenne Muscular Dystrophies at the 30th International Annual Congress of the World Muscle Society</title>
<link>https://6ix.com/company/edgewise-therapeutics-inc/news/edgewise-therapeutics-present-sevasemten-becker-and-duchenne-muscular-dystrophies</link>
<guid isPermaLink="true">https://6ix.com/company/edgewise-therapeutics-inc/news/edgewise-therapeutics-present-sevasemten-becker-and-duchenne-muscular-dystrophies</guid>
<pubDate>Thu, 02 Oct 2025 04:00:00 GMT</pubDate>
<description>BOULDER, Colo., Oct. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced</description>
</item>
<item>
<title>Edgewise Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/edgewise-therapeutics-inc/news/edgewise-therapeutics-reports-second-quarter-2025-financial-results-and-recent</link>
<guid isPermaLink="true">https://6ix.com/company/edgewise-therapeutics-inc/news/edgewise-therapeutics-reports-second-quarter-2025-financial-results-and-recent</guid>
<pubDate>Thu, 07 Aug 2025 04:00:00 GMT</pubDate>
<description>– Announced positive top-line data from the open-label extension MESA trial of sevasemten in participants with Becker muscular dystrophy who previously</description>
</item>
<item>
<title>Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies</title>
<link>https://6ix.com/company/edgewise-therapeutics-inc/news/edgewise-therapeutics-reports-positive-results-sevasemten-program-becker-and-duchenne</link>
<guid isPermaLink="true">https://6ix.com/company/edgewise-therapeutics-inc/news/edgewise-therapeutics-reports-positive-results-sevasemten-program-becker-and-duchenne</guid>
<pubDate>Thu, 26 Jun 2025 04:00:00 GMT</pubDate>
<description>– New open label data in Becker demonstrated sustained disease stabilization up to three years, reinforcing prior clinical findings – – Ongoing pivotal trial</description>
</item>
<item>
<title>Edgewise Therapeutics to Present at the Annual Goldman Sachs Global Healthcare Conference</title>
<link>https://6ix.com/company/edgewise-therapeutics-inc/news/edgewise-therapeutics-present-annual-goldman-sachs-global-healthcare-conference-2025</link>
<guid isPermaLink="true">https://6ix.com/company/edgewise-therapeutics-inc/news/edgewise-therapeutics-present-annual-goldman-sachs-global-healthcare-conference-2025</guid>
<pubDate>Tue, 03 Jun 2025 04:00:00 GMT</pubDate>
<description>BOULDER, Colo., June 3, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced</description>
</item>
<item>
<title>Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2025</title>
<link>https://6ix.com/company/edgewise-therapeutics-inc/news/edgewise-therapeutics-present-rbc-capital-markets-global-healthcare-conference-may-20</link>
<guid isPermaLink="true">https://6ix.com/company/edgewise-therapeutics-inc/news/edgewise-therapeutics-present-rbc-capital-markets-global-healthcare-conference-may-20</guid>
<pubDate>Wed, 14 May 2025 04:00:00 GMT</pubDate>
<description>BOULDER, Colo., May 14, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced</description>
</item>
<item>
<title>Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/edgewise-therapeutics-inc/news/edgewise-therapeutics-reports-first-quarter-2025-financial-results-and-recent</link>
<guid isPermaLink="true">https://6ix.com/company/edgewise-therapeutics-inc/news/edgewise-therapeutics-reports-first-quarter-2025-financial-results-and-recent</guid>
<pubDate>Thu, 08 May 2025 04:00:00 GMT</pubDate>
<description>– Announced positive top-line results from Phase 2 CIRRUS-HCM trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) – – Strengthened balance sheet with net</description>
</item>
<item>
<title>Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock</title>
<link>https://6ix.com/company/edgewise-therapeutics-inc/news/edgewise-therapeutics-announces-pricing-200-million-underwritten-offering-common</link>
<guid isPermaLink="true">https://6ix.com/company/edgewise-therapeutics-inc/news/edgewise-therapeutics-announces-pricing-200-million-underwritten-offering-common</guid>
<pubDate>Wed, 02 Apr 2025 04:00:00 GMT</pubDate>
<description>BOULDER, Colo., April 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a leading muscle disease biopharmaceutical company, today announced</description>
</item>
</channel>
</rss>